Exhaled breath contains chemical clues to what’s going on inside the body, including diseases like lung cancer.
Intas to pay €42M upfront in Henlius deal; Kymera gets $40M milestone; Pluvicto no longer in short supply
Plus, news from Vicore, Elevate Bio, Monte Rosa Therapeutics and Angitia: Intas, Henlius ink another deal: Intas said Friday it plans to pay €42 million